Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
12:50pm, Thursday, 20'th Feb 2025
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say
10:36am, Thursday, 20'th Feb 2025
Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Stree
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
09:15am, Thursday, 20'th Feb 2025
Insmed (INSM) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to loss of $1.28 per share a year ago.
Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update
07:00am, Thursday, 20'th Feb 2025
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the Upper E
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?
10:30am, Monday, 17'th Feb 2025
Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.
Countdown to Insmed (INSM) Q4 Earnings: Wall Street Forecasts for Key Metrics
10:20am, Monday, 17'th Feb 2025
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qua
Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
11:06am, Thursday, 13'th Feb 2025
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed To Present at March 2025 Investor Conferences
08:00am, Tuesday, 11'th Feb 2025
BRIDGEWATER, N.J. , Feb. 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor
Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025
08:00am, Monday, 10'th Feb 2025
BRIDGEWATER, N.J. , Feb. 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor
Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity
10:30am, Friday, 07'th Feb 2025
Insmed's Arikayce, a treatment for MAC and NTM lung diseases, generated $93.4m in Q3 2023, with full-year revenue guidance of $340m-$360m. Brensocatib, Insmed's lead pipeline candidate for non-CF bron
Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review
09:56am, Friday, 07'th Feb 2025
The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Friday, 07'th Feb 2025
BRIDGEWATER, N.J. , Feb. 7, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025
08:00am, Thursday, 06'th Feb 2025
—Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved— BRIDGEWATER, N.J. , Feb. 6, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq:
Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference
08:00am, Friday, 10'th Jan 2025
--ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ARIK
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Friday, 03'rd Jan 2025
BRIDGEWATER, N.J. , Jan. 3, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
